user

Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

被引：0
|
作者：
Bartsch, R. [1 ]
Harbeck, N. [2 ,3 ]
Wrobel, D. [4 ]
Zaiss, M. [5 ]
Terhaag, J. [6 ]
Guth, D. [7 ]
Distelrath, A. [8 ]
Wuerstlein, R. [2 ,3 ]
Zahn, M. -O. [9 ]
Lueftner, D. [10 ,11 ]
Schwitter, M. [12 ]
Balic, M. [13 ]
Jackisch, C. [14 ]
Mueller, V. [15 ]
Rinnerthaler, G. [16 ]
Schmidt, M. [17 ]
Zaman, K. [18 ]
Schinkoethe, T. [19 ]
Gorray, M. [20 ]
Breitenstein, U. [21 ]
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] LMU Univ Hosp, Dept OB GYN, Breast Ctr, Munich, Germany
[3] LMU Univ Hosp, CCC Munich, Munich, Germany
[4] Sozialstiftung Bamberg Klinikum Bruderwald, Bamberg, Germany
[5] Oncol Practice, Freiburg, Germany
[6] Rottal Inn Clin, Eggenfelden, Germany
[7] Gyneco Oncol Practice Dr Guth, Plauen, Germany
[8] Praxisgemeinschaft Onkol & Urol, Wilhelmshaven, Germany
[9] MVZ Onkol Kooperat Harz, Goslar, Germany
[10] Immanuel Hosp Mark Schweiz, Brandenburg, Germany
[11] Med Univ Brandenburg Theodor Fontane, Brandenburg, Germany
[12] Kantonsspital Graubunden, Chur, Switzerland
[13] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria
[14] Sana Klinikum Offenbach, Dept Gynecol & Obstet, Offenbach, Germany
[15] Univ Hosp Hamburg Eppendorf, Dept Gynecol & Obstet, Hamburg, Germany
[16] Paracelsus Med Univ Salzburg, Dept Internal Med 3, Salzburg, Austria
[17] Univ Hosp Mainz, Dept Gynecol, Mainz, Germany
[18] Lausanne Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland
[19] CANKADO Serv GmbH, Kirchheim, Germany
[20] Pierre Fabre Pharma GmbH, Freiburg, Germany
[21] Brust Zentrum Zurich, Div Oncol, Zurich, Switzerland
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P014
引用
下载
收藏
页码：S20 / S21
页数：2
相关论文
共 42 条
  • [1] Interim analysis (n=200) of ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib in the clinical routine
    Bartsch, R.
    Harbeck, N.
    Wrobel, D.
    Zaiss, M.
    Terhaag, J.
    Guth, D.
    Distelrath, A.
    Wuerstlein, R.
    Zahn, M. -O
    Lueftner, D.
    Schwitter, M.
    Balic, M.
    Jackisch, C.
    Mueller, V
    Rinnerthaler, G.
    Schmidt, M.
    Zaman, K.
    Schinkoethe, T.
    Vannier, C.
    Breitenstein, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 170 - 171
  • [2] Interim analysis (n=200) from ELEANOR: a multinational, prospective, non-interventional study among patients with HER2+and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine
    Bartsch, Rupert
    Harbeck, Nadia
    Wrobel, Denise
    Zaiss, Matthias
    Terhaag, Jurgen
    Guth, Dagmar
    Distelrath, Andrea
    Wuerstlein, Rachel
    Zahn, Mark-Oliver
    Luftner, Diana
    Schwitter, Michael
    Balic, Marija
    Jackisch, Christian
    Muller, Volkmar
    Rinnerthaler, Gabriel
    Schmidt, Marcus
    Zaman, Khalil
    Schinkothe, Timo
    Resch, Anna
    Breitenstein, Urs
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
    Harbeck, N.
    Wrobel, D.
    Zaiss, M.
    Guth, D.
    Distelrath, A.
    Terhaag, J.
    Lorenz, A.
    Bartsch, R.
    Breitenstein, U.
    Schwitter, M.
    Balic, M.
    Jackisch, C.
    Mueller, V.
    Rinnerthaler, G.
    Schmidt, M.
    Zaman, K.
    Schinkoethe, T.
    Lueftner, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S157 - S157
  • [4] Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
    Lueftner, Diana
    Bartsch, Rupert
    Breitenstein, Urs
    Balic, Marija
    Jackisch, Christian
    Mueler, Volkmar
    Rinnerthaler, Gabriel
    Schmidt, Marcus
    Schwitter, Michael
    Zaman, Khalil
    Wrobel, Denise
    Guth, Dagmar
    Terhaag, Juergen
    Zaiss, Matthias
    Distelrath, Andrea
    Lorenz, Andreas
    Schinkoethe, Timo
    Harbeck, Nadia
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 20 - 21
  • [5] Extended adjuvant treatment of patients with HER2+early breast cancer with neratinib: a multicentric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)
    Harbeck, N.
    Bartsch, R.
    Jackisch, C.
    Mueller, V
    Schmidt, M.
    Balic, M.
    Rinnerthaler, G.
    Luftner, D.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (06) : E35 - E36
  • [6] Extended adjuvant treatment of patients with HER2+early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)
    Harbeck, N.
    Bartsch, R.
    Jackisch, C.
    Mueller, V
    Schmidt, M.
    Balic, M.
    Rinnerthaler, G.
    Lueftner, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 158 - 158
  • [7] First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib
    Luftner, Diana
    Bartsch, Rupert
    Breitenstein, Urs
    Balic, Marija
    Jackisch, Christian
    Muller, Volkmar
    Rinnerthaler, Gabriel
    Schmidt, Marcus
    Schwitter, Michael
    Zaman, Khalil
    Wrobel, Denise
    Guth, Dagmar
    Terhaag, Jurgen
    Zaiss, Matthias
    Schinkothe, Timo
    Harbeck, Nadia
    CANCER RESEARCH, 2022, 82 (04)
  • [8] ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor (HER2) positive, early breast cancer (eBC) observing real-life extended adjuvant treatment with neratinib and concurrent use of the eHealth solution CANKADO
    Harbeck, N.
    Lueftner, D.
    Breitenstein, U.
    Jackisch, C.
    Mueller, V.
    Schmidt, M.
    Balic, M.
    Rinnerthaler, G.
    Schwitter, M.
    Zaman, K.
    Wrobel, D.
    Guth, D.
    Terhaag, J.
    Zaiss, M.
    Schinkoethe, T.
    Bartsch, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S444 - S444
  • [9] Extended adjuvant treatment of patients with HER2+early breast cancer with neratinib: a multi-centric, prospective, noninterventional study (NIS) in Germany and Austria (ELEANOR)
    Bartsch, R.
    Lueftner, D.
    Balic, M.
    Rinnerthaler, G.
    Jackisch, C.
    Mueller, V.
    Schmidt, M.
    Harbeck, N.
    BREAST, 2021, 56 : S18 - S18
  • [10] Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria and Switzerland: interim results of the prospective, observational ELEANOR study
    Harbeck, Nadia
    Wrobel, Denise
    Zaiss, Matthias
    Terhaag, Juergen
    Guth, Dagmar
    Distelrath, Andrea
    Zahn, Mark-Oliver
    Wuerstlein, Rachel
    Lorenz, Andreas
    Bartsch, Rupert
    Breitenstein, Urs
    Schwitter, Michael
    Balic, Marija
    Jackisch, Christian
    Mueller, Volkmar
    Rinnerthaler, Gabriel
    Schmidt, Marcus
    Zaman, Khalil
    Schinkoethe, Timo
    Resch, Anna
    Valenti, Roberta
    Lueftner, Diana
    BREAST CARE, 2024, 19 (01) : 1 - 9
12345